A Phase 1 trial that is testing Modex's vaccine against the Epstein-Barr virus, a strong risk factor for MS, has dosed its ...

With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

GSK, Pfizer, Johnson & Johnson, Reynolds American, Novartis, Imperial Brands, Cipla Limited, British American Tobacco, Merck ...

The American Chamber of Commerce in Vietnam has appointed doctor Dam Thi Hoang Lan, with decades of experience in healthcare, ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC).

The recipient in Changsha, the capital of Hunan province, became the first man on the Chinese mainland to receive the HPV ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...